Radioligand-binding study of noribogaine, a likely metabolite of ibogaine

@article{Pearl1995RadioligandbindingSO,
  title={Radioligand-binding study of noribogaine, a likely metabolite of ibogaine},
  author={Sandra M. Pearl and Katherine Herrick-Davis and Milt Teitler and Stanley D. Glick},
  journal={Brain Research},
  year={1995},
  volume={675},
  pages={342-344}
}
Characterization of multiple sites of action of ibogaine.
Pharmacological screen for activities of 12-hydroxyibogamine: a primary metabolite of the indole alkaloid ibogaine
TLDR
Ibogaine’s ability to alter drug-seeking behavior may be due to combined actions of the parent drug and metabolite at key pharmacological targets that modulate the activity of drug reward circuits.
Noribogaine is a G-protein biased κ-opioid receptor agonist
Ibogaine: a potent noncompetitive blocker of ganglionic/neuronal nicotinic receptors.
TLDR
In vivo, ibogaine at 10 mg/kg completely blocked epibatidine-elicited antinociception in mice, a response that is mediated by central nicotinic receptor channels, and this response could contribute to the antiaddictive properties of Ibogaine.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 11 REFERENCES
Effects of spiradoline mesylate, a selective kappa-opioid-receptor agonist, on the central dopamine system with relation to mouse locomotor activity and analgesia.
TLDR
Results suggest that inhibition of the dopaminergic pathway in the brain by spiradoline may be involved in its suppression of locomotor activity, but not in its analgesia; whereas, stimulation of the dopamine pathway by morphine seems to function in both behaviors: enhancement of locomot activity and inhibition of analgesia.
Abbreviated Ibogaine Congeners. Synthesis and Reactions of Tropan-3-yl-2- and -3-indoles. Investigation of an Unusual Isomerization of 2-Substituted Indoles Using Computational and Spectroscopic Techniques
The syntheses of several N-methyltropan-3-ylindoles, designed as conge- ners of ibogaine, are described. The synthetic approach to N-methyltro- pan-3-yl-2-indole revealed that the tropanyl 3'-center
Differential involvement of ventral tegmental mu, delta and kappa opioid receptors in modulation of basal mesolimbic dopamine release: in vivo microdialysis studies.
TLDR
Both mu and delta receptor agonist appear capable of increasing ventral striatal DA and DA-metabolite concentrations through selective actions on their preferred class of opioid receptors in the VTA.
Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats.
  • G. Di Chiara, A. Imperato
  • Biology, Psychology
    Proceedings of the National Academy of Sciences of the United States of America
  • 1988
The effect of various drugs on the extracellular concentration of dopamine in two terminal dopaminergic areas, the nucleus accumbens septi (a limbic area) and the dorsal caudate nucleus (a
...
1
2
...